Burning Rock Dx (NASDAQ: BNR) is committed to providing NGS-based testing for late-stage cancer patients, global biomarker detection and companion diagnostic development services to pharmaceutical partners, and NGS-based multi-cancer early detection testing.
We focus on providing multi-dimensional tumor genomic data solutions, multi-modal clinical trial solutions, integrated CDx development and commercialization, and precision patient recruitment for pharmaceutical companies, thereby efficiently facilitating the entire process of anti-cancer drug development.